The effect of risedronate (2.5 mg once daily) on femoral strength was evaluated using Advanced Hip Assessment (AHA) for the first time in Japan. In total, 104 patients with primary osteoporosis and available data on bone mineral density (BMD; lumbar spine/proximal femur), urinary NTx (cross-linked N-telopeptides of type I collagen) and AHA-based parameters collected before and after 4 months of risedronate therapy were included in the analyses. Change and percentage change from baseline in these parameters were determined. Percentage change in femur strength index was 7.9 ± 21.1% and 5.5 ± 18.0% for the right and left femurs, respectively; both increases were statistically significant. Cross-sectional moment of inertia, cross-sectional area and mean neck width in the femoral neck region of interest also increased significantly in both femurs. Percentage change in lumbar spine BMD (L2 -L4) was 3.0 ± 3.7%, and proximal femoral BMD was 1.1 ± 3.1% and 0.7 ± 3.2% in the right and left femurs, respectively, all showing a significant increase from baseline. Percentage change in urinary NTx was -41.5 ± 30.5%, which was a significant decrease. Using AHA, this study showed that, in patients with primary osteoporosis, risedronate improved BMD and bone quality, thereby enhancing femoral strength as early as 4 months after treatment initiation.
Introduction
At the National Institutes of Health (NIH) Osteoporosis Consensus Conference in 1991, osteoporosis was defined as a "Disease characterized by low bone mass and abnormal microstructure of the bone tissue and associated with increased bone fragility and fracture risk". 1 At the NIH Consensus Conference in 2001, osteoporosis was defined as a "Skeletal disease characterized by a decrease in bone strength and associated with an increase in fracture risk," and it was specified that "Bone strength is comprised of two components, bone density and bone quality". 2 The changes to the NIH definition described above clearly demonstrate that osteoporosis is a disease characterized, not only by a decrease in bone mass, but also by a decrease in bone strength, with bone strength influenced by bone quality M Takakuwa, K Otsuka, M Konishi et al. Effects of risedronate on femoral strength (structure, bone metabolism, microfractures and calcification). 1, 2 This change in definition resulted from many clinical studies conducted in the 1990s showing that osteoporosis cannot be explained without the concept of bone quality. 3 These studies also identified the various components of bone quality. While 70% of bone strength can be accounted for by bone density, the remaining 30% is comprehensively attributed to bone quality. 3 Bone quality includes both structural properties and material properties that are significantly related to bone remodelling and that influence bone strength. Structural properties include the macroscopic trabecular structure of cancellous bone and the porosity of cortical bone, whereas material properties include the degree of calcification, crystal size, collagen and microdamage. Of the components of bone quality, bone turnover markers have already been used in the clinical assessment of fracture risk and therapeutic efficacy. 4 In recent years, the clinical assessment of bone geometry and microstructure has also become applicable to clinical practice.
Hip structure analysis (HSA), a noninvasive technique designed to evaluate proximal femoral geometry and calculate femoral strength using dual energy X-ray absorptiometry (DXA) is increasingly used in clinical practice. 5 Software for the analysis of femoral strength, Advanced Hip Assessment (AHA), has been specifically designed for use with the GE Healthcare X-ray bone densitometer (GE Healthcare Life Sciences, Piscataway, NJ, USA) and, when used in combination with regular software for femoral measurements, ensures both the measurement of proximal femoral density and the simultaneous automatic analysis of femoral strength. 6 Calculation of femoral strength is based on proximal femoral density, femoral configuration, neck shaft angle of the femur, and patients' height and body weight; the femoral geometry parameters are shown in Fig. 1 . The AHA-based femoral strength index (FSI) is calculated according to the following formula: femoral strength/fall force. The FSI is, therefore, an estimate of the ability of the hip to withstand a fall on the greater trochanter. It has been reported that a higher FSI (> 1), i.e. femoral strength > fall force, indicates a lower fracture risk than for a low FSI (< 1), i.e. femoral strength < fall force, where femoral strength is low. 6 The AHA-based analysis of bone strength is a method that assesses those aspects of bone quality that affect bone strength. Few studies have been conducted using AHA to evaluate the effects of bisphosphonates. Risedronate is a bisphosphonate that is widely used in the treatment of osteoporosis and the present study aimed to evaluate its effects on femoral strength, bone mineral density (BMD; lumbar spine/proximal femur), and urinary NTx (cross-linked Ntelopeptides of type I collagen).
Patients and methods

PATIENTS AND TREATMENT
This retrospective, observational study included Japanese patients diagnosed with primary osteoporosis and treated with risedronate at the Takakuwa Orthopaedic Nagayama Clinic, Asahikawa City, Japan, between April 2005 and November 2007. Those patients who had available data on urinary NTx, lumbar spine BMD, proximal femoral BMD and AHA-based parameters, both before and after 4 months of risedronate therapy (2.5 mg once daily), were included in the analyses. Patients without complete data were excluded from the study. All patients were not taking any other drugs/treatments that may have M Takakuwa, K Otsuka, M Konishi et al.
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affected the risedronate therapy.
The study protocol was approved by the local ethics committee of the Takakuwa Orthopaedic Nagayama Clinic, Asahikawa City, Japan, and patients participating in the study provided verbal informed consent.
ASSESSMENTS
All assessments were made before and after 4 months of risedronate therapy. The following parameters were assessed using standard laboratory procedures: urinary NTx; lumbar spine BMD; right and left proximal femoral BMD (femoral neck BMD; Ward's triangle BMD, trochanter BMD, inter-trochanter BMD and total BMD). The following AHA-based parameters were also assessed as described previously 6 and shown in Fig. 1 : hip axis length (HAL); femoral strength index (FSI); cross-sectional moment of inertia (CSMI); cross-sectional area (CSA); angle between the shaft axis and the femoral neck axis (θ); angle between the shaft axis and the vertical (α); distance from the centre of gravity to the superior margin of the femoral neck (y); distance from the centre of the femoral head to the CSMI (d1); distance from the centre of the femoral head to the shaft axis (d2); and mean neck width in the femoral neck region of interest (d3).
STATISTICAL ANALYSIS
Data were analysed using the SAS ® software package, version 9.1.3 (SAS Institute Inc., Cary, NC, USA). For each parameter, the mean ± SD was calculated for the baseline and post-treatment values (i.e. before and after 4 months of risedronate therapy, respectively), and for the change and percentage change in the parameters from FIGURE 1: Femur geometry, showing the parameters used for analysis of femoral strength by Advanced Hip Assessment (AHA): CSMI, cross-sectional moment of inertia (mm 4 ); CSA, cross-sectional area (mm 2 ); d1, distance from the centre of the femoral head to the CSMI (mm); d2, distance from the centre of the femoral head to the shaft axis (mm); d3, mean neck width in the femoral neck region of interest (ROI) (mm); F, fall force; Fc, compressive force; M, bending force; y, distance from the centre of gravity to the superior margin of the femoral neck (mm); α, angle between the shaft axis and the vertical; θ, angle between the shaft axis and the femoral neck axis 
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baseline to 4 months and paired t-tests were used to analyse these changes. A P-value < 0.05 was considered to be statistically significant. Pearson's product-moment correlation coefficients were calculated for the correlation between AHA parameters and the percentage change from baseline in urinary NTx or BMD (lumbar spine and proximal femur): a correlation coefficient > 0.4 was considered to indicate a definite positive correlation.
Results
Of 275 patients enrolled in the study, 104 patients (100 females and four males; mean age ± SD 69.2 ± 9.1 years) had available data for urinary NTx, lumbar spine BMD, proximal femoral BMD and AHA-based parameters, both before and after 4 months of risedronate therapy, and were included in the analyses.
Patients' baseline characteristics are shown in Table 1 .
All data for urinary NTx, lumbar spine BMD, right and left proximal femoral BMD and AHA-based parameters collected before and after 4 months of risedronate therapy are shown in Table 2 . After 4 months of therapy, the percentage change from baseline in FSI showed a significant increase in both the right (P < 0.001) and left (P = 0.003) femurs. In addition, CSMI, CSA and d3 significantly increased in both femurs (P < 0.01) and HAL significantly decreased in both femurs (P < 0.05). The percentage change in lumbar spine BMD compared with baseline showed a significant increase at L1 -L4 and at L2 -L4 (P < 0.001), as did the percentage change in total proximal BMD in the right (P = 0.001) and left (P = 0.020) femurs. Femoral neck BMD (right, P < 0.001; left, P = 0.002) and inter-trochanter BMD (right, P = 0.035; left, P = 0.019) significantly increased in both femurs compared with baseline. In the right femur, Ward's triangle BMD (P = 0.040) also significantly increased. Urinary NTx showed a significant decrease (P < 0.001) ( Table 2) . Assessment of Pearson's product-moment correlation coefficients between AHA parameters and urinary NTx or BMD (lumbar spine/proximal femur), showed that the left CSA was positively correlated (i.e. r > 0.4) with proximal femur BMD (r = 0.426), but none of the other parameters showed a correlation (Table 3 ). In the assessment of correlation between FSI and each of the other AHA parameters, FSI was positively correlated (i.e. r > 0.4) with CSMI (r = 0.503), CSA (r = 0.663) and d3 (r = 0.425) in the left femur (Fig. 2) , and was positively correlated with CSA (r = 0.521) in the right femur ( Fig. 3 ).
Discussion
Two comparative studies to evaluate FSI by AHA-based DXA and quantitative computed tomography showed that the two methods were highly correlated. 7, 8 In addition, the 9 in a clinical study in the USA involving 365 Caucasian women with fractures compared with 2141 counterparts without fractures. Their study showed that HAL and FSI were independent, useful predictive factors for fracture risk, and that fracture could be more reliably predicted by comprehensive assessment of T score, HAL and FSI. 9 These reports indicated that AHAbased diagnosis may ensure easy and accurate measurement of bone density and quality as well as assessment of bone strength in clinical practice. A decrease in bone strength due to osteoporosis results in fractures associated with even simple motions in daily life, impairing activities of daily living and decreasing quality of life (QOL), as well as causing death in some cases. 10 In particular, femoral neck fracture often results in confinement to bed and significantly impairs QOL in the elderly. 11 According to a 2002 national survey, there were 117 900 patients (25 300 males and 92 600 females) with proximal femoral fractures in Japan, with annual incidence showing an increasing trend. 12 In addition, the incidence of proximal femoral fractures increased with age. 12 For early prevention of proximal femoral fractures, a challenging issue in the ageing population in Japan, early diagnosis and treatment based on simple measurement of femoral BMD and geometry is likely to be very important. Some postmenopausal women have an increased risk of fracture even though bone density is not as low as those diagnosed with osteoporosis. 13 Once fracture occurs, the risk of recurrent fracture within 1 year increases. Fracture recurs within 1 year in as many as 20% of patients. 14 Physicians have several therapeutic options, not only to reduce fracture risk within a short period of time, but HAL, hip axis length; CSMI, cross-sectional moment of inertia; CSA, cross-sectional area; d1, distance from the centre of the femoral head to the CSMI; d2, distance from the centre of the femoral head to the shaft axis; d3, mean neck width in the femoral neck region of interest; y, distance from the centre of gravity to the superior margin of the femoral neck; α, angle between the shaft axis and the vertical; θ, angle between the femoral shaft axis and the femoral neck axis; FSI, femoral strength index. Risedronate is the only bisphosphonate that can reduce the risk of symptomatic (painful) vertebral and non-vertebral fractures as early as 6 months after the start of treatment. 15, 16 In a practice-based, observational study, Silverman et al. 17 found that the incidence of proximal femoral and non-vertebral fractures was significantly lower in risedronate-treated patients compared with alendronate-treated patients at 6 and 12 months after the start of treatment, and reported that risedronate effectively prevented fractures earlier than alendronate. In a 1-year, double-blinded, comparative study in post-menopausal patients with breast cancer who received chemotherapy, van Londen et al. 18 measured femoral strength, using HSA, and reported that risedronate significantly improved the FSI compared with placebo. This rapid fracture-preventive effect of risedronate may be partly attributed to its potent inhibitory activity on farnesyl diphosphate synthase. 19 Treatment with risedronate in the present study significantly increased the FSI and BMD (lumbar spine/proximal femur), as well as resulting in a significant decrease in urinary NTx, as early as 4 months after the start of treatment in patients with primary osteoporosis, thereby supporting data that have indicated risedronate can act rapidly to prevent fractures. In addition, FSI was highly correlated with CSA and d3, indicating that risedronate increased the width of the proximal femur and, therefore, CSMI (a deformability index that depends on the cross-sectional configuration of the proximal femur; greater CSMI indicates less deformability) by acting on the cortical bone and, ultimately, increasing the FSI. Although there was no placebo group in this study, significant clinical improvement in FSI from baseline was demonstrated and, as a higher FSI has been shown to indicate a 
